SK Bioscience Co Ltd
KRX:302440

Watchlist Manager
SK Bioscience Co Ltd Logo
SK Bioscience Co Ltd
KRX:302440
Watchlist
Price: 39 600 KRW -2.1% Market Closed
Market Cap: 3.1T KRW

P/OCF
Price to OCF

-24.2
Current
31.5
Median
19.3
Industry
Lower than median
Lower than industry value

Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.

P/OCF
-24.2
=
Market Cap
3.1T KRW
/
Operating Cash Flow
-128B KRW
Market Cap P/OCF
KR
SK Bioscience Co Ltd
KRX:302440
3.1T KRW -24.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -220 067.6
US
Abbvie Inc
NYSE:ABBV
344.4B USD 18.3
US
Amgen Inc
NASDAQ:AMGN
156.2B USD 13.6
US
Gilead Sciences Inc
NASDAQ:GILD
132.7B USD 12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
130.9B USD -265.8
US
Epizyme Inc
F:EPE
94.1B EUR -511.2
AU
CSL Ltd
ASX:CSL
121.6B AUD 26.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
65.6B USD 14.8
US
Seagen Inc
F:SGT
39.3B EUR -82.5
NL
argenx SE
XBRU:ARGX
34.6B EUR -473
 
KR
SK Bioscience Co Ltd
KRX:302440
Average P/OCF: 17.1
Negative Multiple: -24.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 067.6
US
Abbvie Inc
NYSE:ABBV
18.3
US
Amgen Inc
NASDAQ:AMGN
13.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -265.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -511.2
AU
CSL Ltd
ASX:CSL
26.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -82.5
NL
argenx SE
XBRU:ARGX
Negative Multiple: -473

P/OCF Forward Multiples

Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/OCF
N/A
2-Years Forward
P/OCF
N/A
3-Years Forward
P/OCF
N/A